Document is current
Any future updates will be listed below
-
Authors
Allott, Kelly https://orcid.org/0000-0002-0640-4634
Yassin, Walid https://orcid.org/0000-0001-9612-0485
Alameda, Luis https://orcid.org/0000-0002-8621-2885
Billah, Tashrif
Borders, Owen
Buccilli, Kate
Carrión, Ricardo E. https://orcid.org/0000-0002-6393-392X
Castillo-Passi, Rolando I. https://orcid.org/0000-0002-9446-074X
Cho, Kang Ik K. https://orcid.org/0000-0001-7135-3848
Chin, Kota
Coleman, Michael J.
Colton, Beau-Luke
Corral, Sebastián
Dwyer, Dominic https://orcid.org/0000-0003-3949-5867
Gundersen, Kristina Ballestad https://orcid.org/0000-0003-3277-4564
Gur, Ruben C.
Hoftman, Gil D.
Jacobs, Grace R. https://orcid.org/0000-0001-9961-6507
Kelly, Sinead
Lewandowski, Kathryn E. https://orcid.org/0000-0003-1477-6187
Marcy, Patricia J.
Matneja, Priya
McLaughlin, Danielle
Nunez, Angela R.
Parsa, Setari
Penzel, Nora https://orcid.org/0000-0003-1624-386X
Ray, Susan
Reinen, Jenna M.
Ruparel, Kosha
Sand, Michael S.
Santorelli, Gennarina
Seitz-Holland, Johanna https://orcid.org/0000-0002-1815-2681
Spark, Jessica
Tamayo, Zailyn
Thompson, Andrew
Tod, Sophie
Wannan, Cassandra M. J. https://orcid.org/0000-0003-1317-4635
Wickham, Alana
Wood, Stephen J. https://orcid.org/0000-0003-4186-5919
Zoupou, Eirini
Addington, Jean https://orcid.org/0000-0002-8298-0756
Anticevic, Alan
Arango, Celso https://orcid.org/0000-0003-3382-4754
Breitborde, Nicholas J. K.
Broome, Matthew R. https://orcid.org/0000-0002-6963-8884
Cadenhead, Kristin S. https://orcid.org/0000-0002-5952-4605
Calkins, Monica E.
Chen, Eric Yu Hai https://orcid.org/0000-0002-5247-3593
Choi, Jimmy
Conus, Philippe
Corcoran, Cheryl M. https://orcid.org/0000-0002-8902-4353
Cornblatt, Barbara A.
Ellman, Lauren M.
Fusar-Poli, Paolo
Gaspar, Pablo A. https://orcid.org/0000-0002-9682-5327
Gerber, Carla
Glenthøj, Louise Birkedal
Horton, Leslie E.
Hui, Christy Lai Ming
Kambeitz, Joseph https://orcid.org/0000-0002-8988-3959
Kambeitz-Ilankovic, Lana
Keshavan, Matcheri
Kim, Sung-Wan https://orcid.org/0000-0002-6739-2163
Koutsouleris, Nikolaos https://orcid.org/0000-0001-6825-6262
Kwon, Jun Soo https://orcid.org/0000-0002-1060-1462
Langbein, Kerstin
Mamah, Daniel
Diaz-Caneja, Covadonga M. https://orcid.org/0000-0001-8538-3175
Mathalon, Daniel H. https://orcid.org/0000-0001-6090-4974
Mittal, Vijay A. https://orcid.org/0000-0001-9017-5119
Nordentoft, Merete
Pearlson, Godfrey D.
Perkins, Diana O. https://orcid.org/0000-0001-9396-2206
Perez, Jesus
Powers, Albert R. III https://orcid.org/0000-0003-3057-5043
Rogers, Jack
Sabb, Fred W.
Schiffman, Jason
Shah, Jai L. https://orcid.org/0000-0002-7549-6990
Silverstein, Steven M. https://orcid.org/0000-0002-0699-0960
Smesny, Stefan
Strauss, Gregory P.
Thompson, Judy L.
Upthegrove, Rachel https://orcid.org/0000-0001-8204-5103
Verma, Swapna K.
Wang, Jijun https://orcid.org/0000-0001-5427-7425
Wolf, Daniel H. https://orcid.org/0000-0002-9731-8781
Pasternak, Ofer
Bouix, Sylvain https://orcid.org/0000-0003-1326-6054
McGorry, Patrick D.
Kane, John M.
Kahn, Rene S. https://orcid.org/0000-0001-5909-8004
Bearden, Carrie E. https://orcid.org/0000-0002-8516-923X
Shenton, Martha E. https://orcid.org/0000-0003-4235-7879
Woods, Scott W. https://orcid.org/0000-0002-3103-5228
Nelson, Barnaby
,
Stone, William S.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U24MH124629, U01MH124631, U01MH124639)
Wellcome Trust (220664/Z/20/Z, 220664/A/20/Z)
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 24 December 2024
First Online: 24 March 2025
Change Date: 14 April 2025
Change Type: Update
Change Details: In this article, an updated link to the video interview was provided for inclusion in the final version. This has now been incorporated into both the HTML and PDF versions of the article.
Competing interests
: The authors declare the following competing interests: K.A. is on the Australian Cognitive Impairment Associated with Schizophrenia Advisory Board for Boehringer Ingelheim and receives honorary funds; D.D. has received honorary funds for one educational seminar for CSL Sequiris; A.A. is a cofounder, serves as a member of the Board of Directors, as a scientific adviser, and holds equity in Manifest Technologies, Inc.; and is a coinventor on the following patent: Anticevic A, Murray JD, Ji JL: Systems and Methods for NeuroBehavioral Relationships in Dimensional Geometric Embedding, PCT International Application No. PCT/US2119/022110, filed Mar 13, 2019; E.C. has received speaker fees at non-promotional educational events; P.F.P. has received research funds or personal fees from Lundbeck, Angelini, Menarini, Sunovion, Boehringer Ingelheim, Proxymm Science, Otsuka, outside the current study; J.K. has received speaking or consulting fees from Janssen, Boehringer Ingelheim, ROVI and Lundbeck; C.D.C. has received grant support from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation and honoraria or travel support from Angelini, Janssen, and Viatris; R.U. has received speaker fees at non promotional educational event: Otsuka: Consultancy for Viatris and Springer HealtCCare. Honorary General Secretary British Association for Psychopharmacology (unpaid); JMK is a consultant to or receives honoraria and/or travel support and/or speakers bureau: Alkermes, Allergan, Boehringer-Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS Therapeutics, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, Karuna Therapeutics/Bristol Meyer-Squibb, LB Pharmaceuticals, Mapi, Maplight, Merck, Minerva, Neurocrine, Newron, Novartis, NW PharmaTech, Otsuka, Roche, Saladax, Sunovion, Teva. Advisory Boards: Alkermes, Boehringer-Ingelheim, Cerevel, Click Therapeutics, Karuna/BMS, Lundbeck, Merck, Newron, Novartis, Otsuka, Sumitomo, Teva, Terran Grant Support: Lundbeck, Janssen, Otsuka, Sunovion Shareholder: Cerevel (public/stock), HealthRhythms (private/stock options), Karuna/BMS (public), LB Pharmaceuticals, Inc. (private/stock options), North Shore Therapeutics (private/stock), Vanguard Research Group (private/40% owner) Receives Royalties: Up to Date; RSK provides consulting to Alkermes, Boehringer-Ingelheim; S.W.W. has received speaking fees from the American Psychiatric Association and from Medscape Features. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. He owns stock in NW PharmaTech; C.A. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda; G.D.H. has been a consultant for Bristol Myers Squibb; P.J.M. has been a consultant for Otsuka and TEVA; and Z.T. has been a consult for Manifest Technologies. All other authors report no competing interests. C.M.C. is an Associate Editor of Schizophrenia.
